证券代码：688137 证券简称：近岸蛋白 公告编号：2023-021 苏州近岸蛋白质科技股份有限公司 关于首次公开发行部分限售股上市流通公告 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意苏州近岸蛋白质科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]1626 号），公司首次公开发行人 民币普通股（A）股 17,543,860 股，并于 2022 年 9 月 29 日在上海证券交易所科创 板挂牌上市。首次公开发行股票完成后，公司总股本为 70,175,439 股，其中有流 通限制或限售安排的股票数量为 53,911,380 股，占公司发行后总股本的 76.8237%， 无流通限制及限售安排的股票数量为 16,264,059 股，占公司发行后总股本的 23.1763%。具体情况详见公司于 2022 年 9 月 28 日披露于上海证券交易所网站 （www.sse.com.cn）的《苏州近岸蛋白质科技股份有限公司首次公开发行股票科 创板上市公告书》。 本次上市流通的限售股为公司首次公开发行限售股，限售股股东数量为 1 名， 吴江东运创业投资有限公司（以下简称"东运创投"），锁 ...

民生证券股份有限公司 关于苏州近岸蛋白质科技股份有限公司 2023 年半年度持续督导跟踪报告 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为苏州 近岸蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"）首次公开发 行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、 《上海证券交易所科创板股票上市规则》以及《科创板上市公司持续监管办法（试 行）》等有关法律法规和规范性文件的要求，负责近岸蛋白上市后的持续督导工 作，并出具本持续督导跟踪报告。 2023 年半年度，民生证券对近岸蛋白的持续督导情况工作总结如下： | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制 | 本持续督导期间，保荐机构已建立健全 | | 1 | 度，并针对具体的持续督导工作制定相 | 并有效执行了持续督导制度，并制定了 | | | 应的工作计划 | 相应的工作计划 | | | 根据中国证监会相关规定，在持续督导 | 本持续督导期间，保荐机构已与近岸蛋 | | | 工作开始前，与上市公司或相关当事人 | 白签订承销及保荐协议，该协 ...

Financial Performance - The overall performance of the company has significantly declined year-on-year during the reporting period[4] - The company's operating revenue for the first half of 2023 was CNY 74.69 million, a decrease of 55.10% compared to CNY 166.34 million in the same period last year[19] - The net profit attributable to shareholders for the same period was CNY 12.36 million, down 82.66% from CNY 71.30 million year-on-year[19] - The basic earnings per share decreased by 86.67% to CNY 0.18, down from CNY 1.35 in the same period last year[20] - The company's total revenue for the reporting period was 74.69 million yuan, a year-on-year decrease of 55.10%, with net profit attributable to the parent company at 12.36 million yuan, down 82.66%[120] Revenue and Growth - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2023, representing a 25% year-over-year growth[12] - User data indicates a growth in active users, reaching 1.2 million, which is a 15% increase compared to the previous period[12] - Revenue from regular business, excluding pandemic-related products and mRNA-related products, reached 49.28 million yuan, representing a year-on-year growth of 15.38%[120] - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 30%[12] Research and Development - The company plans to increase its R&D budget by 15% in 2024 to accelerate innovation and product pipeline development[12] - The proportion of R&D investment to operating revenue rose to 33.88%, an increase of 23.05 percentage points year-on-year, reflecting the company's commitment to expanding its R&D efforts in mRNA vaccines and antibody drugs[22] - The total R&D expenditure for the reporting period was CNY 25,305,398.88, a 40.51% increase compared to the previous year, with R&D expenses accounting for 33.88% of total revenue, up 23.05 percentage points year-on-year[101][102] - The company has launched 75 new products during the reporting period, with over 100 products currently under research and development[89] Market Position and Strategy - The company is expanding its market presence in Europe, targeting a 10% market share by the end of 2024[12] - A strategic acquisition of a biotechnology firm was completed, enhancing the company's R&D capabilities and expected to generate synergies worth 30 million RMB annually[12] - The company has established a broad customer base for mRNA raw enzymes, supplying over 100 vaccine production clients, including Watson Bio and Aibao Bio[40] - The company aims to transform from a technology-driven approach to providing comprehensive solutions for clients, supporting innovation and upgrades in the biopharmaceutical sector[30] Financial Risks and Compliance - The report has not been audited, indicating that the financial data may be subject to further verification[5] - The company faces risks related to core technology leakage, talent retention, and intensified market competition in the recombinant protein industry[131][136] - The company has established a commitment to disclose any changes in shareholding to comply with relevant laws and regulations[182] - The company has not reported any unfulfilled commitments during the reporting period[181] Corporate Governance - The board of directors has ensured the authenticity, accuracy, and completeness of the semi-annual report[4] - The company has not disclosed any special arrangements for corporate governance[5] - The company has not proposed any profit distribution or capital reserve transfer plans during this reporting period[5] - There are no significant changes in the shareholding structure or shareholder situation reported[7] Product Development and Innovation - New product development includes the launch of a recombinant protein product line, expected to contribute an additional 50 million RMB in revenue by Q4 2023[12] - The company has developed a total of 3,082 types of target and factor proteins, an increase of 34 types, including a new transmembrane protein NaPi2b, which is a potential target for lung and ovarian cancer treatment[31] - The company has produced a total of 629 types of enzymes and reagents, an increase of 38 types, including new GMP-grade RNase R for circular RNA applications and rapid dye qPCR reagents that significantly enhance experimental efficiency[34] - The company has developed nearly 10 RNA reference materials, including Cas9 mRNA and luciferase mRNA, to support gene editing and delivery vector formulation[90] Market Trends and Industry Insights - The global mRNA vaccine industry is recognized for its short development cycle and rapid production speed, gaining significant attention[38] - The domestic mRNA vaccine industry is rapidly developing, with companies like Watson Bio and Aibo Bio focusing on mRNA vaccine drug development[37] - The recombinant protein industry is characterized by high technical barriers and rapid market demand changes, necessitating continuous product iteration and proactive R&D strategies[57] - The in vitro diagnostic (IVD) industry in China experienced a growth rate exceeding 30% in 2022, but is expected to decline in 2023, with conventional business growth projected at around 10% excluding COVID-19 impacts[67] Shareholder Commitments and Stock Management - The company’s actual controller and major shareholders have committed to not transferring or requesting the repurchase of shares for 36 months post-IPO[181] - The company will ensure compliance with the regulations governing shareholding changes and transfers[186] - Shareholders are required to report any changes in their shareholdings and comply with relevant laws and regulations regarding shareholding changes[191] - The company plans to repurchase shares through the stock exchange within 12 months after the shareholder meeting approves the stock repurchase plan, with the repurchase price not exceeding the latest audited net asset value per share[195]

证券代码：688137 证券简称：近岸蛋白 公告编号：2023-019 苏州近岸蛋白质科技股份有限公司 2023 年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次计提减值准备情况概述 根据《企业会计准则》相关规定和公司会计政策，为真实、准确反映公司财 务状况、资产价值及经营成果，公司对截至 2023 年 6 月 30 日合并报表范围内的 各类资产进行了全面检查和减值测试，基于谨慎性原则，公司对可能发生减值损 失的资产计提相应减值准备。 （二）计提资产减值准备 经公司及子公司对截至 2023 年 6 月 30 日存在可能发生减值迹象的资产进行 全面清查和资产减值测试后，计提各项减值准备共计 12,608,710.83 元，计入的 报告期间为 2023 年 1 月 1 日至 2023 年 6 月 30 日，明细如下表： 币种：人民币 单位：元 | 项 目 | 计提减值准备金额 | | | --- | --- | --- | | 一、信用减值损失 | | -572,750.57 | | 其中： ...

根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》的规定，将苏州近岸 蛋白质科技股份有限公司（以下简称本公司或公司）2023 年半年度募集资金存放与使用 情况报告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意苏州近岸蛋白质科技股份有限公司首次公开 发行股票注册的批复》证监许可[2022]1626 号文件，本公司向社会公开发行人民币普通 股（A 股）1,754.3860 万股，每股发行价为 106.19 元，应募集资金总额为人民币 186， 298.25 万元，根据有关规定扣除发行费用 12,078.67 万元后，实际募集资金金额为 174,219.58 万元。该募集资金已于 2022 年 9 月到账。上述资金到账情况业经容诚会计 师事务所（特殊普通合伙）《验资报告》（容诚验字[2022]200Z0058 号）验证。公司对 募集资金采取了专户存储管理。 证券代码：688137 证券简称：近岸蛋白 公告编号：2023-018 苏州近岸蛋白质科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的专 ...

苏州近岸蛋白质科技股份有限公司独立董事 关于第一届董事会第十一次会议相关事项的独立意见 根据《上市公司独立董事规则》《苏州近岸蛋白质科技股份有限公司章程》(以 下简称"《公司章程》")等相关规定,我们作为苏州近岸蛋白质科技股份有限 公司(以下简称"公司")的独立董事,参加了公司第一届董事会第十一次会议, 在认真全面审阅有关文件资料后,对第一届董事会第十一次会议审议的相关事 项,基于独立判断的立场,发表意见如下: 《关于〈2023 年半年度募集资金存放与实际使用情况专项报告〉的议案》 经核查,公司 2023年半年度募集资金的存放和使用符合中国证监会、上海 证券交易所关于上市公司募集资金存放和使用的相关监管要求,准确、完整地反 映了 2023年半年度公司募集资金的存放、使用与管理情况,募集资金实际使用 情况与公司信息披露情况一致,符合《上市公司监管指引第2号一上市公司募集 资金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号一规范运作》,不存在募集资金违规存放和使用的情形,亦不存在变相改变 募集资金用途、损害股东利益的情形。我们同意公司编制的《2023 年半年度募 集资金存放与实际使用情 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2023-020 苏州近岸蛋白质科技股份有限公司 第一届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）第一届监事会第九 次会议于 2023 年 8 月 26 日在公司会议室以现场加通讯会议相结合的方式召开， 会议通知已于 2023 年 8 月 16 日以电子邮件方式送达全体监事。会议应出席监事 3 人，实际出席监事 3 人，会议由监事会主席李德彬先生召集并主持。本次会议 的召集、召开程序和方式符合《公司法》和《公司章程》的有关规定，会议决议 合法、有效。经与会监事审议讨论，本次会议做出如下决议： 二、监事会会议审议情况 （一）审议通过《关于 2023 年半年度报告及其摘要的议案》 经审议，监事会认为：公司《2023 年半年度报告》及其摘要的编制和审议程 序规范合法，符合法律、法规、公司章程及监管机构的规定，公司《2023 年半年 度报告》公允地反映了公司报告期内的财务状 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2023-016 苏州近岸蛋白质科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 06 月 15 日(星期四) 下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 06 月 08 日(星期四) 至 06 月 14 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 IR@novoprotein.com.cn 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日发布公司 2022 年度报告，为便于广大投资者更全面深入 地了解公司 2022 年度经营成果、财务状况，公司 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[16]. - The company's operating revenue for 2022 was ¥264,553,718, a decrease of 22.62% compared to ¥341,895,855.16 in 2021[28]. - The net profit attributable to shareholders decreased by 39.32% to ¥90,416,734.36 from ¥149,005,616.48 in the previous year[30]. - The net profit after deducting non-recurring gains and losses fell by 47.88% to ¥77,596,888.20 compared to ¥148,869,293.75 in 2021[30]. - The company achieved operating revenue of RMB 87,842,857.29, a year-on-year increase of 12% compared to RMB 78,494,682.3 in 2021[33]. - The net profit attributable to shareholders was RMB 39,897,088.36, representing a 27% increase from RMB 31,405,202.5 in the previous year[33]. - The company reported cash flow from operating activities of RMB 7,020,963.80, an increase from RMB 4,114,032.74 in 2021[33]. - The company reported a significant increase in cash and cash equivalents, with a net increase of 739,935,737.21 RMB, up 512.77% from the previous year[162]. - The company achieved operating revenue of ¥264,553,718, a decrease of 22.91% compared to the previous year, with product revenue at ¥255,579,959.75[144]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year, representing a 20% year-over-year growth[194]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% year-over-year growth[196]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2022, representing a 20% growth compared to the previous year[199]. Market Presence and Client Engagement - As of the end of the reporting period, the company has over 100 clients in the mRNA vaccine production sector, indicating a growing market presence[4]. - The company is expanding its market presence, targeting D new regions, which is expected to enhance overall market share by E%[16]. - The company is actively pursuing market expansion through the development of new diagnostic reagents and mRNA vaccine candidates[118]. - The company plans to increase marketing personnel and enhance customer engagement to expand its business in emerging markets[148]. - The company is focusing on sustainability initiatives, aiming to reduce carbon emissions by 25% over the next five years[194]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of 300 million allocated for this purpose[199]. Research and Development - The R&D budget has increased by G%, focusing on advancements in gene editing and mRNA vaccine technologies[16]. - The company launched over 100 new innovative products during the reporting period, enhancing its product offerings[44]. - The company added 34 new R&D personnel, increasing its investment in research and development[44]. - The company reported a total R&D investment of approximately ¥41.1 million, representing a 20.55% increase compared to the previous year, with R&D expenses accounting for 15.54% of total revenue[115]. - The company is developing a one-stop service for innovative antibody research and mRNA synthesis, successfully serving dozens of clients[112]. - The company is actively collaborating with research institutions and universities to advance the development of mRNA vaccines in basic research[61]. - The company has developed 23 core technologies related to protein design, modification, and production, which remain unchanged during the reporting period[97]. - The company has established a comprehensive technology platform for antibody discovery and diagnostic reagents, leveraging expertise in molecular biology and protein engineering[97]. - The company is focusing on mRNA technology, aiming to provide related CRO services and expand into emerging fields like organoids and cell therapy[178]. Competitive Landscape and Risks - The company faces risks of revenue decline in its mRNA raw enzyme and diagnostic antibody businesses due to industry competition and uncertainties in client product development[4]. - The recombinant protein and related technology service market is expanding rapidly, attracting more domestic and international competitors, which may increase competitive pressure on the company[5]. - There is a risk of increased inventory levels due to market changes, which could lead to unsold products and potential write-downs[6]. - The company acknowledges the potential for intensified market competition and the need for increased R&D investment to maintain its competitive edge[5]. - The company faces risks related to the fluctuation of product sales prices, which have shown a downward trend[139]. Strategic Initiatives - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, totaling RMB 35,087,719.50, which represents 38.8% of the net profit attributable to shareholders for 2022[8]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2022 fiscal year[8]. - The company will enhance its marketing and service capabilities to improve customer coverage and satisfaction[178]. - The company aims to increase market share by expanding its business team and enhancing digital marketing efforts[181]. - The company will consider investments and acquisitions in related upstream and downstream industries to enhance its business and industry layout[184]. Operational Efficiency - The gross margin improved to I%, reflecting better cost management and operational efficiencies[16]. - The company has implemented a comprehensive quality management system that includes periodic audits of raw material suppliers and stringent testing for residual impurities[128]. - The company has successfully implemented a quality management system compliant with GMP standards, ensuring product safety and stability through rigorous quality control measures[126]. - The company achieved significant advancements in mRNA vaccine drug development, including the launch of GMP-grade nucleotides and modified nucleotides, contributing to clinical projects and regulatory approvals for multiple partners[109]. Shareholder Engagement - The company held its first extraordinary general meeting of 2022 on March 4, 2022, where all proposals were approved by shareholders[187]. - The second extraordinary general meeting took place on November 28, 2022, with all proposals also receiving shareholder approval[188]. - The total pre-tax remuneration for key management personnel during the reporting period amounted to CNY 577.42 million[191]. - The chairman and general manager, Zhu Huaxing, maintained a shareholding of 15,343,004 shares throughout the year[190]. - The company’s board of directors and senior management have remained stable with no significant changes in shareholdings[190].

Financial Performance - Operating revenue for 2022 was ¥264,553,718, a decrease of 22.62% compared to ¥341,895,855 in 2021[21]. - Net profit attributable to shareholders was ¥90,416,734, down 39.32% from ¥149,005,616 in the previous year[21]. - Basic earnings per share decreased by 57% to ¥1.59 from ¥3.73 in 2021[23]. - The net cash flow from operating activities dropped significantly by 95.24% to ¥3,376,641 from ¥70,966,537 in 2021[21]. - The net profit after deducting non-recurring gains and losses was ¥77,596,888, a decrease of 47.88% from ¥148,869,293 in 2021[21]. - The company reported a significant increase in net assets attributable to shareholders, rising by 511.33% to ¥2,199,386,246.43 from ¥359,772,635.07 in 2021[22]. - The quarterly operating revenue for Q4 2022 was ¥51,923,824.83, showing a decline compared to previous quarters[25]. - In 2022, the company achieved operating revenue of RMB 264.55 million, a year-on-year decrease of 22.62%, and a net profit attributable to the parent company of RMB 90.42 million, with a decrease of 47.88% in net profit after deducting non-recurring gains and losses[34]. - The company reported a total revenue of 1.2 billion in 2022, representing a year-over-year growth of 15%[165]. - The company provided guidance for 2023, expecting revenue to grow by 10% to 1.32 billion[165]. Dividend Policy - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, totaling RMB 35,087,719.50, which accounts for 38.8% of the net profit attributable to shareholders for 2022[6]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2022 fiscal year[6]. - The company has a cash dividend policy that emphasizes a stable and reasonable return to investors, with a minimum cash distribution of 30% of the average distributable profit over the last three years[186]. - In mature stages without major capital expenditure, the cash dividend proportion should be at least 80% of the profit distribution[186]. - The company has not proposed any cash profit distribution plan during the reporting period despite having positive distributable profits[190]. Market and Competition - The company faces risks of revenue decline in its mRNA raw enzyme and diagnostic antibody businesses due to industry cycle impacts and uncertainties in the mRNA vaccine sector[4]. - The recombinant protein and related technology service market is expanding, but increased competition from new entrants may pressure the company's market position[5]. - The company anticipates further market competition as more players enter the recombinant protein industry, which may impact market share and pricing strategies[125]. - The company is focused on advancing mRNA technology platforms, including new delivery systems and adjuvants, to enhance vaccine efficacy[50]. - The company aims to expand its market presence through strategic collaborations and technological advancements in mRNA production[51]. Research and Development - Research and development expenses accounted for 15.54% of operating revenue, an increase of 56 basis points from 9.97% in 2021[23]. - The company established a professional R&D team of 235 members, contributing to continuous product and technology innovation[39]. - The company has developed 23 core technologies related to protein design, modification, and production, showcasing its advanced capabilities in the field[85]. - The company is actively enhancing its R&D investment in mRNA-related products and technologies to improve vaccine development services[149]. - The company has developed high-quality mRNA production key raw materials, including T7 RNA polymerase and mRNA Cap 2'-O-methyltransferase, which have reached international advanced levels[109]. Operational Efficiency - The company emphasizes internal control and management optimization, enhancing its operational efficiency and compliance with business processes[40]. - The production process adheres to ISO9001:2015 and ISO13485:2016 quality management systems, ensuring product quality and stability[59]. - The company has established a complete quality management system, ensuring product safety and stability through rigorous quality control measures[115]. - Operating expenses were reduced by 5% due to improved operational efficiencies[165]. - The company has implemented a comprehensive quality control system for large-scale production of recombinant proteins and antibodies[54]. Strategic Initiatives - The company successfully listed on the Sci-Tech Innovation Board on September 29, 2022, raising a net amount of RMB 1.74 billion for R&D, industrialization, and marketing network development[34]. - The company completed a strategic acquisition for 200 million, enhancing its product portfolio[165]. - The company is exploring potential acquisitions to bolster its product portfolio, with a budget of $100 million allocated for this purpose[168]. - The company has established partnerships with over 100 vaccine production clients, including Watson Bio and Livanda Bio, to ensure quality and supply of mRNA raw materials[51]. Employee and Governance - The company has a total workforce of 675 employees, a year-on-year increase of 32.47%, with 22.86% holding a master's degree or higher[39]. - The company emphasizes talent development, collaborating with renowned universities and research institutions to cultivate a skilled R&D team[116]. - The company has established a governance framework that includes a board of directors and various committees to ensure compliance and effective decision-making[155]. - The total remuneration for directors, supervisors, and senior management is determined based on internal management regulations and industry standards[173]. - The company has established specialized committees under the board, including the audit committee, nomination committee, remuneration and assessment committee, and strategic committee[176]. Risks and Challenges - The company acknowledges potential risks related to inventory management and the possibility of product obsolescence due to market changes[5]. - The company faces risks related to the potential decline in sales from its non-COVID business segments if it fails to achieve scale in other areas[118]. - The company is exposed to risks from changes in tax policies that could affect its preferential tax rate of 15% for high-tech enterprises[123]. - The company reported a significant reliance on a few major customers, with over 50% of sales attributed to a single customer[139]. Environmental and Social Responsibility - The company has established environmental protection mechanisms and complies with relevant laws and regulations, including the Environmental Protection Law of the People's Republic of China[196]. - There were no administrative penalties due to environmental issues during the reporting period[195]. - The company emphasizes employee rights protection, ensuring timely payment of social insurance and promoting employee training and career development[200].